ArticleAdvances in urology2026
Clinical Significance of Pathological Lymph Node Status in Prostate Cancer Patients Undergoing Radical Prostatectomy: A 25-Year Institutional Cohort Study.
Article in Advances in urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: While the therapeutic value of pelvic lymph node dissection (PLND) remains controversial, the pathological lymph node status itself may provide important prognostic information after radical prostatectomy (RP). Methods: Among 610 consecutive patients who underwent RP between January 2000 and December 2019, with follow-up through December 2024, we retrospectively analyzed 445 patients with intermediate- or high-risk disease according to the D'Amico classification who underwent PLND. Patients were stratified according to the pathological lymph node status into pN0 ( Results: The median age of the cohort was 68 years. BCR occurred in 26% of the pN0 patients, with a median time to BCR of 29 months, and in 41% of pN1 patients, with a median time to BCR of 47 months. During follow-up, 38 all-cause deaths (9.1%) occurred in the pN0 group and 9 (31.0%) in the pN1 group. Kaplan-Meier analysis showed no significant difference in BCR-free survival between groups, whereas OS was significantly worse in the pN1 group (hazard ratio: 2.768; 95% confidence interval: 1.315-5.829; Conclusions: Pathological lymph node positivity is a strong independent predictor of inferior OS in patients undergoing RP for localized prostate cancer. These findings underscore the need for tailored postoperative management strategies in patients with node-positive disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.